StockData
Belite Bio, Inc logo

Belite Bio, Inc (BLTE) stock

BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 5/30
$157.72−4.84 (-2.98%)

Close on Nov 17, 2026Market cap $6.20BP/E –Yield –

Belite Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$84.21M. The highest annual figure on record is -$5.74M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$84.21M–
FY2024Dec 31, 2024-$40.00M–
FY2023Dec 31, 2023-$31.67M–
FY2022Dec 31, 2022-$12.82M–
FY2021Dec 31, 2021-$9.80M–
FY2020Dec 31, 2020-$5.74M–

More Belite Bio figures

See a number that looks wrong?